KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

(2021) David M. Briere et al.   MOLECULAR CANCER THERAPEUTICS

Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma

(2020) Changqing Xie et al.   CLINICAL CANCER RESEARCH

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future

(2020) Eric S Christenson et al.   LANCET ONCOLOGY

Myc instructs and maintains pancreatic adenocarcinoma phenotype

(2020) Nicole M Sodir et al.   Cancer Discovery

Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses

(2020) Julianna Blagih et al.   Cell Reports

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications

(2020) Claudio Luchini et al.   GUT

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

(2020) Shota Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.

(2020) Satoshi Yuki et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.

(2020) François Ghiringhelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

(2020) Keisuke Yamamoto et al.   NATURE

Metastatic Pancreatic Cancer: ASCO Guideline Update

(2020) Davendra P.S. Sohal et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion

(2020) Li-Lian Gan et al.   Cancers

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?

(2020) Friederike Inga Nollmann et al.   Biomedicines

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).

(2019) Zev A. Wainberg et al.   JOURNAL OF CLINICAL ONCOLOGY

IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma

(2019) Alex B. Blair et al.   JOURNAL OF CLINICAL INVESTIGATION

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

(2019) Wenting Liao et al.   CANCER CELL

Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy

(2019) Qiang Zhang et al.   CANCER RESEARCH

Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer

(2019) Nithya Sivaram et al.   JOURNAL OF CLINICAL INVESTIGATION

Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer

(2019) Timothy J Humpton et al.   Cancer Discovery

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

(2019) Eileen M. O’Reilly et al.   JAMA Oncology

Checkpoint inhibitors in pancreatic cancer

(2019) Andreas Henriksen et al.   CANCER TREATMENT REVIEWS

Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma

(2019) Adam L. Burrack et al.   Cell Reports

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

(2019) Suneel D. Kamath et al.   ONCOLOGIST

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications

(2019) Xiaomeng Liu et al.   Molecular Cancer

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer

(2018) J Smeby et al.   ANNALS OF ONCOLOGY

Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice

(2018) Ping He et al.   GASTROENTEROLOGY

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Angiogenesis in pancreatic cancer: current research status and clinical implications

(2018) Shuo Li et al.   ANGIOGENESIS

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies

(2018) Qiang Wang et al.   CANCER LETTERS

Cancer Neoantigens

(2018) Ton N. Schumacher et al.   Annual Review of Immunology

Development of PARP and Immune-Checkpoint Inhibitor Combinations

(2018) Ross A Stewart et al.   CANCER RESEARCH

Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy

(2018) Gang Wang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

OncogenicKrasdrives invasion and maintains metastases in colorectal cancer

(2017) Adam T. Boutin et al.   GENES & DEVELOPMENT

Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.

(2017) Zev A. Wainberg et al.   JOURNAL OF CLINICAL ONCOLOGY

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

(2017) Chunwan Lu et al.   JNCI-Journal of the National Cancer Institute

Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis

(2017) Maria Teresa Salcedo Allende et al.   PANCREAS

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops

(2017) Guido Eibl et al.   SEMINARS IN CANCER BIOLOGY

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

(2017) Andrew M. Waters et al.   Cold Spring Harbor Perspectives in Medicine

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

(2017) Chunwan Lu et al.   JNCI-Journal of the National Cancer Institute

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling

(2016) Ralph Gruber et al.   GASTROENTEROLOGY

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

Pancreatic cancer

(2016) Terumi Kamisawa et al.   LANCET

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

(2016) Emma M. Kerr et al.   NATURE

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

(2016) Filippos Kottakis et al.   NATURE

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma

(2016) S Murakami et al.   ONCOGENE

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

(2015) Gregory L. Beatty et al.   GASTROENTEROLOGY

The consensus molecular subtypes of colorectal cancer

(2015) Justin Guinney et al.   NATURE MEDICINE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

(2014) M. Aglietta et al.   ANNALS OF ONCOLOGY

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice

(2014) Bridget P. Keenan et al.   GASTROENTEROLOGY

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

(2014) W. Zhang et al.   Science Signaling

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

(2013) D. E. Sanford et al.   CLINICAL CANCER RESEARCH

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas

(2012) Efsevia Vakiani et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis

(2011) R. B. Corcoran et al.   CANCER RESEARCH

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells

(2009) J. Yun et al.   SCIENCE